Aurora Spine’s Patent Related to Its Polyaxial ZIP® ISP Allowed by the United States Patent Office

Aurora Spine Corporation (TSXV:ASG) announced today the allowance of its United States Patent Application No.: 14/732,240 entitled “POLYAXIAL INTERSPINOUS FUSION IMPLANT AND BONE GROWTH STIMULATION SYSTEM.” In addition to Aurora’s implant family of ZIP® ISPs, including its ZIP Ultra®, ZIP 51™, ZIP LP™ and Dyna-ZIP™, this patent application covers the company’s first polyaxial implant design.
“The polyaxial ZIP® Interspinous patent allowance is another milestone in Aurora Spine’s history. Our latest patent will be issued for our newest interspinous device design that permits for full polyaxial maneuverability of the implant components in difficult situations during minimally invasive fusion cases. The newly allowed patent features our already patented ONE-STEP™ locking mechanism that eliminates the use of a set screw in Aurora’s Screwless Procedure™ surgeries,” said Laszlo Garamszegi, Chief Technology Officer of Aurora Spine.“Aurora is changing spine surgery, and we are thrilled that our newest patent has been allowed by the United States Patent and Trademark Office (USPTO). This patent further validates the modern advancements of our Screwless technology,” said Trent Northcutt, President and CEO of Aurora Spine, “and it maintains our commitment to introduce advanced, minimally invasive spine surgery technologies.”This is Aurora’s second allowed U.S. patent. Aurora Spine has several other U.S. and international patent applications pending directed to the ZIP system and its future technologies.About Aurora SpineAurora Spine is an early stage company focused on bringing new solutions to the spinal implant market through a series of screwless, innovative, minimally invasive, regenerative spinal implant technologies. Aurora Spine continues to position itself at the forefront of spinal surgery procedures, focusing on minimally invasive spine surgery technologies. Aurora Spine is changing spine surgery by focusing on disruptive technologies following the Company’s commitment to – Simplifying the Complex.Forward-Looking StatementsThis news release contains forward-looking information that involves substantial known and unknown risks and uncertainties, most of which are beyond the control of Aurora Spine, including, without limitation, those listed under “Risk Factors” and “Cautionary Statement Regarding Forward-Looking Information” in Aurora Spine’s final prospectus (collectively, “forward-looking information”). Forward-looking information in this news release includes information concerning the proposed use and success of the company’s products in surgical procedures. Aurora Spine cautions investors of Aurora Spine’s securities about important factors that could cause Aurora Spine’s actual results to differ materially from those projected in any forward-looking statements included in this news release. Any statements that express, or involve discussions as to, expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts and may be forward-looking and may involve estimates, assumptions and uncertainties which could cause actual results or outcomes to differ unilaterally from those expressed in such forward-looking statements. No assurance can be given that the expectations set out herein will prove to be correct and, accordingly, prospective investors should not place undue reliance on these forward looking statements. These statements speak only as of the date of this press release and Aurora Spine does not assume any obligation to update or revise them to reflect new events or circumstances.For more information, please contact:
Aurora Spine Corporation
Trent Northcutt
President and Chief Executive Officer
(760) 424-2004
Eric Fronk
Chief Financial Officer
(760) 424-2004
www.aurora-spine.com